drugset / Trial / NCT01708889

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

NCT01708889

Phase 1 Completed 43 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.

Timeline

Start
2012-09
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon Lambda-1a Protein / enzyme biologic 180 ug Subcutaneous